Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Home
▹
Exit Individual PI Data
Member Profile
Deepak Vashishth
Personal Information
Title
Director
Expertise
Bone
Institution
Rensselaer Polytechnic Institute
Newsletter?
Not signed up.
Data Summary
Type
Count
Grants/SubContracts
1
Progress Reports
1
Publications
0
Protocols
0
Committees
1
Grants/Applications
Progress Reports
Publications
Presentations
Protocols
Committees
In Vivo Removal of Advanced Glycation End-products Rescues Type-II Diabetes Skeletal Fragility
Bone fracture, a serious diabetic complication, contributes significantly to health care costs and affect quality of life including increased morbidity and mortality. Risk of fracture is increased 3-folds in patients with type-II diabetes (T2D) despite normal to high bone mineral density (BMD). Consequently, the increase fracture risk in T2D patients is paradoxical and suggests that there may be diabetes-associated detrimental alterations within bone extracellular matrix. This study seeks to determine and remove such modifications to rescue T2D associated bone fragility. In particular, non-enzymatic glycation (NEG) of bone, a post translational modification of long-lived extracellular matrix proteins by sugars, is associated with T2D and linked to fragility fractures. Pentosidine (PEN) is the only established clinical marker of NEG in bone but it represents <1% of total fluorescent Advanced Glycation End-products (fAGEs). Here for the first time, we show that Carboxymethyl-lysine (CML), a non-fluorescent AGE, is 40-100 times more prevalent in bone matrix than PEN, and CML is highly correlated to bone toughness (a measure of bone fracture). More importantly, AGEs in bone can be cleaved in-vitro by phenacylthiazolium-based compounds. However, AGE based prediction and rescue of T2D bone fragility needs to be established in a relevant in-vivo model in order to pursue a larger (R01) federally funded investigation. Thus, the overall goal of the proposed pilot and feasibility study is to determine the contribution of AGEs to diabetic fractures and rescue T2D bone fragility by removal of AGEs. Using a validated preclinical diet-induced rat model, we will test whether removal of AGEs with phenacylthiazolium chloride (PTC) in-vivo rescues T2D bone fragility by measuring CML, PEN, and fAGEs (by UPLC and fluorometric assays), bone strength, and fracture toughness. The findings of our pilot study will provide a new understanding of the role of AGEs in T2D-induced skeletal fragility and establish feasibility of new strategies to predict, manage, and mitigate T2D fractures.
Progress Reports
Drag a column header and drop it here to group by that column
Application
Complete Date
Report
Options
In Vivo Removal of Advanced Glycation End-products Rescues Type-II Diabetes Skeletal Fragility (Vashishth, Deepak)
10/8/2021
View Progress Report Document
Annual Reports
No uploaded documents found.
Publication
Altmetrics
Submitted By
PubMed ID
Status
Options
No records to display.
No uploaded documents found.
No protocols found.
Name
Description
Steering Committee
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
Curation Flag Information
Display Stats
New comment to be added:
Flag Active?
OrderID
Experiment
Species
Status
Measurements
Options
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!